Skip to main content
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc. — Investor Relations & Filings

Ticker · SGMT ISIN · US7867001049 LEI · 2549002OT2F8BV0VPD02 US Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2024-11-14 Interim / Quarterly Rep…
Country US United States of America
Listing US SGMT

About Sagimet Biosciences Inc.

https://sagimet.com/

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company that develops novel fatty acid synthase (FASN) inhibitors. These therapeutics are designed to target dysfunctional metabolic and fibrotic pathways resulting from the overproduction of the fatty acid, palmitate. The company's lead product candidate is denifanstat, and its pipeline includes TVB-3567. Sagimet is exploring the application of its FASN inhibitors in treating diseases where dysregulation of fatty acid metabolism plays a key role, such as metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2024
2024-11-14 English
Regulatory Filings 2024
Regulatory Filings
2024-08-27 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from Sagimet Biosciences Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It is a short correspondence related to a regulatory filing process, specifically about the timing of the effectiveness of a registration statement for securities offering. There is no financial data, report content, or detailed presentation. The document is a regulatory communication and does not constitute a full report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (1484 characters), consistent with a regulatory filing letter rather than a full report.
2024-08-22 English
Regulatory Filings 2024
Regulatory Filings
2024-08-19 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 15, 2024, by Sagimet Biosciences Inc. It reports the entry into a material definitive agreement, specifically a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. The content focuses on the details of this financing agreement, including the terms of the ATM offering and related conditions. There are no financial statements or comprehensive financial performance data included, nor is this a report of earnings or management discussion. The document is a current report disclosing a capital raising event and related agreement. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 5922 characters, which is sufficient to contain substantive information about the financing event rather than just an announcement or a brief notice. Hence, the classification is CAP with high confidence.
2024-08-16 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities offerings under the Securities Act of 1933. It includes a base prospectus and a sales agreement prospectus for offering up to $300 million of various securities. The text references the registration process, securities to be offered, and related legal and procedural information. This is not a financial report, earnings release, or management discussion, but a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement, not just an announcement or a brief notice.
2024-08-15 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.